74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
AnaptysBio Inc
Closed
SectorHealthcare
20.48 0.29
Overview
Share price change
24h
Min
19.48
Max
20.62
Income | 11M -22M |
|---|---|
Sales | 13M 43M |
EPS | -0.72 |
Profit margin | -50.528 |
Employees | 136 |
EBITDA | 13M -3.8M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +108.64% upside |
Next Earnings | 7 May 2025 |
|---|
Market Cap | 183M 632M |
|---|---|
Previous open | 20.19 |
Previous close | 20.48 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
AnaptysBio Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
AnaptysBio Inc Forecast
Price Target
By TipRanks
108.64% upside
12 Months Forecast
Average 43 USD 108.64%
High 57 USD
Low 22 USD
Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
